Markets

SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZeneca

Aug 4, 2026 · 06:19 AM ET· updated 2h ago

SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (NYSE:AZN).This

Why It Matters

SOPHiA GENETICS and a big drug company (AstraZeneca) are teaming up to create special tests that help doctors pick the right cancer medicines for each patient. This partnership shows other companies trust SOPHiA's work, which could be good for its business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SOPH5.87

+0.18 (+3.16%)

AZN157.95

-0.02 (-0.01%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.